JP2017522879A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017522879A5 JP2017522879A5 JP2017503488A JP2017503488A JP2017522879A5 JP 2017522879 A5 JP2017522879 A5 JP 2017522879A5 JP 2017503488 A JP2017503488 A JP 2017503488A JP 2017503488 A JP2017503488 A JP 2017503488A JP 2017522879 A5 JP2017522879 A5 JP 2017522879A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- cll
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 72
- 210000004027 cell Anatomy 0.000 claims 46
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 33
- 150000007523 nucleic acids Chemical class 0.000 claims 31
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 claims 27
- 101710188619 C-type lectin domain family 12 member A Proteins 0.000 claims 27
- 230000004048 modification Effects 0.000 claims 25
- 238000012986 modification Methods 0.000 claims 25
- 108020004707 nucleic acids Proteins 0.000 claims 24
- 102000039446 nucleic acids Human genes 0.000 claims 24
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 23
- 229920001184 polypeptide Polymers 0.000 claims 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims 21
- 230000004068 intracellular signaling Effects 0.000 claims 15
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 13
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 12
- -1 CD86 Proteins 0.000 claims 11
- 230000011664 signaling Effects 0.000 claims 10
- 230000000139 costimulatory effect Effects 0.000 claims 9
- 102100022339 Integrin alpha-L Human genes 0.000 claims 8
- 239000012642 immune effector Substances 0.000 claims 8
- 229940121354 immunomodulator Drugs 0.000 claims 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 claims 6
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims 6
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 claims 6
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 6
- 102100032818 Integrin alpha-4 Human genes 0.000 claims 6
- 102100032816 Integrin alpha-6 Human genes 0.000 claims 6
- 102100025390 Integrin beta-2 Human genes 0.000 claims 6
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 102100029197 SLAM family member 6 Human genes 0.000 claims 6
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 claims 6
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 229940127089 cytotoxic agent Drugs 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- 102100024263 CD160 antigen Human genes 0.000 claims 4
- 102100038077 CD226 antigen Human genes 0.000 claims 4
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims 4
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 claims 4
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 claims 4
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 claims 4
- 101001035237 Homo sapiens Integrin alpha-D Proteins 0.000 claims 4
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 claims 4
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims 4
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 claims 4
- 101000633780 Homo sapiens Signaling lymphocytic activation molecule Proteins 0.000 claims 4
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 4
- 102100025323 Integrin alpha-1 Human genes 0.000 claims 4
- 102100039904 Integrin alpha-D Human genes 0.000 claims 4
- 102100022341 Integrin alpha-E Human genes 0.000 claims 4
- 102100022338 Integrin alpha-M Human genes 0.000 claims 4
- 102100022297 Integrin alpha-X Human genes 0.000 claims 4
- 102100025304 Integrin beta-1 Human genes 0.000 claims 4
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 4
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 4
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 claims 4
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 claims 4
- 102000014128 RANK Ligand Human genes 0.000 claims 4
- 108010025832 RANK Ligand Proteins 0.000 claims 4
- 102100027744 Semaphorin-4D Human genes 0.000 claims 4
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 claims 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 2
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 108010056102 CD100 antigen Proteins 0.000 claims 2
- 108010017009 CD11b Antigen Proteins 0.000 claims 2
- 102100027207 CD27 antigen Human genes 0.000 claims 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 108010062802 CD66 antigens Proteins 0.000 claims 2
- 102100027217 CD82 antigen Human genes 0.000 claims 2
- 101710139831 CD82 antigen Proteins 0.000 claims 2
- 102100035793 CD83 antigen Human genes 0.000 claims 2
- 102100037904 CD9 antigen Human genes 0.000 claims 2
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims 2
- 101000585551 Equus caballus Pregnancy-associated glycoprotein Proteins 0.000 claims 2
- 102100022086 GRB2-related adapter protein 2 Human genes 0.000 claims 2
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 2
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims 2
- 101000900690 Homo sapiens GRB2-related adapter protein 2 Proteins 0.000 claims 2
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 2
- 101001046683 Homo sapiens Integrin alpha-L Proteins 0.000 claims 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims 2
- 101001046668 Homo sapiens Integrin alpha-X Proteins 0.000 claims 2
- 101001015037 Homo sapiens Integrin beta-7 Proteins 0.000 claims 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 2
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims 2
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 claims 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 2
- 101001090688 Homo sapiens Lymphocyte cytosolic protein 2 Proteins 0.000 claims 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 2
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 2
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 claims 2
- 101000873418 Homo sapiens P-selectin glycoprotein ligand 1 Proteins 0.000 claims 2
- 101001124867 Homo sapiens Peroxiredoxin-1 Proteins 0.000 claims 2
- 101000692259 Homo sapiens Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Proteins 0.000 claims 2
- 101000702132 Homo sapiens Protein spinster homolog 1 Proteins 0.000 claims 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 2
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 claims 2
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims 2
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims 2
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims 2
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims 2
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 2
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 2
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 claims 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 2
- 108010041100 Integrin alpha6 Proteins 0.000 claims 2
- 108010030465 Integrin alpha6beta1 Proteins 0.000 claims 2
- 102100033016 Integrin beta-7 Human genes 0.000 claims 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 2
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims 2
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 claims 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 2
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 claims 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 2
- 108091008877 NK cell receptors Proteins 0.000 claims 2
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 2
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims 2
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims 2
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims 2
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 claims 2
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 claims 2
- 101710141230 Natural killer cell receptor 2B4 Proteins 0.000 claims 2
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 claims 2
- 102100026066 Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Human genes 0.000 claims 2
- 102100024952 Protein CBFA2T1 Human genes 0.000 claims 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 2
- 208000007660 Residual Neoplasm Diseases 0.000 claims 2
- 102100029216 SLAM family member 5 Human genes 0.000 claims 2
- 102100029198 SLAM family member 7 Human genes 0.000 claims 2
- 102000008115 Signaling Lymphocytic Activation Molecule Family Member 1 Human genes 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 2
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims 2
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims 2
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims 2
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 2
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 2
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims 2
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims 2
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 claims 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 2
- 101001038499 Yarrowia lipolytica (strain CLIB 122 / E 150) Lysine acetyltransferase Proteins 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 230000003750 conditioning effect Effects 0.000 claims 2
- 229960000684 cytarabine Drugs 0.000 claims 2
- 102000003675 cytokine receptors Human genes 0.000 claims 2
- 108010057085 cytokine receptors Proteins 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 102000006495 integrins Human genes 0.000 claims 2
- 108010044426 integrins Proteins 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 229940124302 mTOR inhibitor Drugs 0.000 claims 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 2
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- 102100026121 Flap endonuclease 1 Human genes 0.000 claims 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims 1
- 101000913035 Homo sapiens Flap endonuclease 1 Proteins 0.000 claims 1
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 108091054437 MHC class I family Proteins 0.000 claims 1
- 102000043129 MHC class I family Human genes 0.000 claims 1
- 101001059732 Malassezia furfur Putative peroxiredoxin Proteins 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 102000027581 NK cell receptors Human genes 0.000 claims 1
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006994 Precancerous Conditions Diseases 0.000 claims 1
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 230000005809 anti-tumor immunity Effects 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2014/082602 | 2014-07-21 | ||
| CN2014082602 | 2014-07-21 | ||
| CN2014090500 | 2014-11-06 | ||
| CNPCT/CN2014/090500 | 2014-11-06 | ||
| PCT/US2015/041337 WO2016014535A1 (en) | 2014-07-21 | 2015-07-21 | Treatment of cancer using a cll-1 chimeric antigen receptor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020121501A Division JP2020185001A (ja) | 2014-07-21 | 2020-07-15 | Ｃｌｌ−１キメラ抗原受容体を使用した癌の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017522879A JP2017522879A (ja) | 2017-08-17 |
| JP2017522879A5 true JP2017522879A5 (enExample) | 2018-08-30 |
| JP6736540B2 JP6736540B2 (ja) | 2020-08-05 |
Family
ID=53761606
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017503488A Expired - Fee Related JP6736540B2 (ja) | 2014-07-21 | 2015-07-21 | Ｃｌｌ−１キメラ抗原受容体を使用した癌の処置 |
| JP2020121501A Pending JP2020185001A (ja) | 2014-07-21 | 2020-07-15 | Ｃｌｌ−１キメラ抗原受容体を使用した癌の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020121501A Pending JP2020185001A (ja) | 2014-07-21 | 2020-07-15 | Ｃｌｌ−１キメラ抗原受容体を使用した癌の処置 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10568947B2 (enExample) |
| EP (1) | EP3171882A1 (enExample) |
| JP (2) | JP6736540B2 (enExample) |
| KR (1) | KR20170037625A (enExample) |
| CN (1) | CN107109420A (enExample) |
| AR (1) | AR101829A1 (enExample) |
| AU (2) | AU2015292811B2 (enExample) |
| BR (1) | BR112017000939A2 (enExample) |
| CA (1) | CA2955465A1 (enExample) |
| CO (1) | CO2017000506A2 (enExample) |
| IL (1) | IL250116B (enExample) |
| MX (1) | MX2017001013A (enExample) |
| RU (1) | RU2741120C2 (enExample) |
| SG (2) | SG10201913782UA (enExample) |
| TW (1) | TWI718992B (enExample) |
| WO (1) | WO2016014535A1 (enExample) |
Families Citing this family (151)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4282419A1 (en) | 2012-12-20 | 2023-11-29 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| US9573988B2 (en) | 2013-02-20 | 2017-02-21 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
| JP6647868B2 (ja) | 2013-02-20 | 2020-02-14 | ノバルティス アーゲー | ヒト化抗ＥＧＦＲｖＩＩＩキメラ抗原受容体を用いたがんの処置 |
| WO2014145252A2 (en) | 2013-03-15 | 2014-09-18 | Milone Michael C | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| AU2014348657A1 (en) * | 2013-11-13 | 2016-05-19 | Novartis Ag | mTOR inhibitors for enhancing the immune response |
| ES2918501T3 (es) | 2013-12-19 | 2022-07-18 | Novartis Ag | Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| WO2015112626A1 (en) | 2014-01-21 | 2015-07-30 | June Carl H | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| AU2015244039B2 (en) | 2014-04-07 | 2021-10-21 | Novartis Ag | Treatment of cancer using anti-CD19 chimeric antigen receptor |
| TWI719942B (zh) | 2014-07-21 | 2021-03-01 | 瑞士商諾華公司 | 使用ｃｄ３３嵌合抗原受體治療癌症 |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| SG10201913782UA (en) | 2014-07-21 | 2020-03-30 | Novartis Ag | Treatment of cancer using a cll-1 chimeric antigen receptor |
| BR112017001183A2 (pt) | 2014-07-21 | 2017-11-28 | Novartis Ag | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado |
| MX2017002205A (es) | 2014-08-19 | 2017-08-21 | Novartis Ag | Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer. |
| JP6839074B2 (ja) | 2014-09-17 | 2021-03-03 | ノバルティス アーゲー | 養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング |
| KR20170068504A (ko) | 2014-10-08 | 2017-06-19 | 노파르티스 아게 | 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도 |
| RU2021118125A (ru) | 2014-12-29 | 2022-04-06 | Новартис Аг | Способы получения экспрессирующих химерный антигенный рецептор клеток |
| US11459390B2 (en) | 2015-01-16 | 2022-10-04 | Novartis Ag | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor |
| BR112017013981A2 (pt) * | 2015-01-26 | 2018-01-02 | Cellectis | receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| EP4406604A3 (en) | 2015-03-05 | 2024-10-23 | Fred Hutchinson Cancer Center | Immunomodulatory fusion proteins and uses thereof |
| JP6961490B2 (ja) | 2015-04-08 | 2021-11-05 | ノバルティス アーゲー | Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法 |
| AU2016249005B2 (en) | 2015-04-17 | 2022-06-16 | Novartis Ag | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| EP3286211A1 (en) | 2015-04-23 | 2018-02-28 | Novartis AG | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| CA2986359A1 (en) | 2015-05-20 | 2016-11-24 | Novartis Ag | Pharmaceutical combination of everolimus with dactolisib |
| JP7033453B2 (ja) | 2015-06-30 | 2022-03-10 | セレクティス | 特異的エンドヌクレアーゼを使用した遺伝子不活化によってｎｋ細胞の機能性を改善する方法 |
| CA2992551A1 (en) | 2015-07-21 | 2017-01-26 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
| WO2017040930A2 (en) | 2015-09-03 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Biomarkers predictive of cytokine release syndrome |
| WO2017093969A1 (en) | 2015-12-04 | 2017-06-08 | Novartis Ag | Compositions and methods for immunooncology |
| EP4643874A3 (en) | 2015-12-22 | 2026-02-11 | Novartis AG | Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy |
| CN109153975A (zh) | 2015-12-28 | 2019-01-04 | 诺华股份有限公司 | 制备嵌合抗原受体表达细胞的方法 |
| RU2018127657A (ru) | 2015-12-30 | 2020-01-31 | Новартис Аг | Виды терапии на основе иммуноэффекторных клеток с улучшенной эффективностью |
| MA55746A (fr) * | 2016-01-21 | 2022-03-02 | Novartis Ag | Molécules multispécifiques ciblant cll-1 |
| KR20180118175A (ko) | 2016-03-04 | 2018-10-30 | 노파르티스 아게 | 다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도 |
| EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
| KR20230148844A (ko) * | 2016-03-29 | 2023-10-25 | 유니버시티 오브 써던 캘리포니아 | 암을 표적하는 키메라 항원 수용체 |
| ES2891578T3 (es) | 2016-04-01 | 2022-01-28 | Kite Pharma Inc | Antígeno quimérico y receptores de células T y métodos de uso |
| TWI795133B (zh) | 2016-04-01 | 2023-03-01 | 美商凱特製藥公司 | Ｂｃｍａ結合分子類及彼等之用途 |
| CA3019650C (en) * | 2016-04-01 | 2023-07-25 | Kite Pharma, Inc. | Chimeric receptors and methods of use thereof |
| EP3439675A4 (en) | 2016-04-08 | 2019-12-18 | Purdue Research Foundation | METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY |
| US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| CN109715808A (zh) | 2016-04-15 | 2019-05-03 | 诺华股份有限公司 | 用于选择性蛋白质表达的组合物和方法 |
| SG10202012157QA (en) * | 2016-06-07 | 2021-01-28 | Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft | Chimeric antigen receptor and car-t cells that bind bcma |
| SG11201900344YA (en) | 2016-07-15 | 2019-02-27 | Novartis Ag | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
| AU2017302668B9 (en) | 2016-07-28 | 2023-06-22 | Novartis Ag | Combination therapies of chimeric antigen receptors and PD-1 inhibitors |
| BR112019002035A2 (pt) | 2016-08-01 | 2019-05-14 | Novartis Ag | tratamento de câncer usando um receptor de antígeno quimérico em combinação com um inibidor de uma molécula pró-macrófago m2 |
| US20190307799A1 (en) * | 2016-09-23 | 2019-10-10 | The Regents Of The University Of Michigan | Engineered lymphocytes |
| CN109844126A (zh) | 2016-09-28 | 2019-06-04 | 诺华股份有限公司 | 基于多孔膜的大分子递送系统 |
| DK3523326T3 (da) * | 2016-10-04 | 2020-08-03 | Prec Biosciences Inc | Samstimulerende domæner til anvendelse i genetisk modificerede celler |
| BR112019006781A2 (pt) | 2016-10-07 | 2019-07-30 | Novartis Ag | receptores de antígeno quiméricos para o tratamento de câncer |
| SI3529262T1 (sl) * | 2016-10-21 | 2021-12-31 | Inserm - Institut National De La Sante Et De La Recherche Medicale | Postopki za spodbujanje odgovora T-celic |
| CN110114070A (zh) | 2016-11-23 | 2019-08-09 | 诺华公司 | 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法 |
| ES2912408T3 (es) | 2017-01-26 | 2022-05-25 | Novartis Ag | Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos |
| US11649288B2 (en) | 2017-02-07 | 2023-05-16 | Seattle Children's Hospital | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| WO2018160731A1 (en) | 2017-02-28 | 2018-09-07 | Novartis Ag | Shp inhibitor compositions and uses for chimeric antigen receptor therapy |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| RU2019130504A (ru) | 2017-02-28 | 2021-03-30 | Вор Байофарма, Инк. | Композиции и способы ингибирования линиеспецифических белков |
| CN119409836A (zh) | 2017-03-17 | 2025-02-11 | 弗雷德哈钦森癌症中心 | 免疫调节融合蛋白及其用途 |
| WO2018175636A2 (en) | 2017-03-22 | 2018-09-27 | Novartis Ag | Compositions and methods for immunooncology |
| WO2019000146A1 (zh) * | 2017-06-26 | 2019-01-03 | 深圳市博奥康生物科技有限公司 | 一种人程序性死亡受体1基因的siRNA及其应用 |
| AU2018351050B2 (en) | 2017-10-18 | 2025-09-18 | Novartis Ag | Compositions and methods for selective protein degradation |
| RU2020116579A (ru) | 2017-10-25 | 2021-11-25 | Новартис Аг | Способы получения клеток, экспрессирующих химерный антигенный рецептор |
| US20210179709A1 (en) | 2017-10-31 | 2021-06-17 | Novartis Ag | Anti-car compositions and methods |
| US20200371091A1 (en) * | 2017-11-30 | 2020-11-26 | Novartis Ag | Bcma-targeting chimeric antigen receptor, and uses thereof |
| WO2019108065A1 (en) * | 2017-12-01 | 2019-06-06 | Merus N.V. | Use of bispecific antibody and il-15 for combination therapy |
| EP3729081B1 (en) * | 2017-12-21 | 2025-02-19 | F. Hoffmann-La Roche AG | Car-t cell assay for specificity test of novel antigen binding moieties |
| CN111247429B (zh) * | 2017-12-21 | 2025-03-28 | 豪夫迈·罗氏有限公司 | 用于新颖抗原结合模块的特异性测试的通用报告细胞测定法 |
| US12539308B2 (en) | 2018-01-08 | 2026-02-03 | The Trustees Of The University Of Pennsylvania | Immune-enhancing RNAs for combination with chimeric antigen receptor therapy |
| MX2020007338A (es) * | 2018-01-09 | 2020-11-06 | H Lee Moffitt Cancer Ct & Res | Composiciones y métodos para el direccionamiento a tipos de cáncer que expresan clec12a. |
| US11311576B2 (en) | 2018-01-22 | 2022-04-26 | Seattle Children's Hospital | Methods of use for CAR T cells |
| US12312416B2 (en) | 2018-02-06 | 2025-05-27 | Seattle Children's Hospital | Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors |
| AU2019225174B2 (en) | 2018-02-23 | 2025-11-20 | Endocyte, Inc. | Sequencing method for CAR T cell therapy |
| MX2020009272A (es) * | 2018-03-06 | 2021-01-08 | Univ Pennsylvania | Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos. |
| EP3775902B1 (en) | 2018-04-04 | 2023-02-22 | F. Hoffmann-La Roche AG | Diagnostic assays to detect tumor antigens in cancer patients |
| WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| WO2019222579A1 (en) * | 2018-05-17 | 2019-11-21 | St. Jude Children's Research Hospital, Inc. | Chimeric antigen receptors with myd88 and cd40 costimulatory domains |
| EP3801769A1 (en) | 2018-05-25 | 2021-04-14 | Novartis AG | Combination therapy with chimeric antigen receptor (car) therapies |
| WO2019237035A1 (en) | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| WO2019241315A1 (en) | 2018-06-12 | 2019-12-19 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| TWI890660B (zh) | 2018-06-13 | 2025-07-21 | 瑞士商諾華公司 | Bcma 嵌合抗原受體及其用途 |
| CN108866088B (zh) * | 2018-06-20 | 2023-06-09 | 上海恒润达生生物科技股份有限公司 | 靶向cll-1嵌合抗原受体及其用途 |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| GB201813178D0 (en) * | 2018-08-13 | 2018-09-26 | Autolus Ltd | Cell |
| CA3110837A1 (en) | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| EP3844265A2 (en) | 2018-08-31 | 2021-07-07 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
| EP4635978A2 (en) | 2018-08-31 | 2025-10-22 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
| EP3850013A4 (en) * | 2018-09-10 | 2022-10-05 | Nanjing Legend Biotech Co., Ltd. | SINGLE DOMAIN ANTIBODIES AGAINST CLL1 AND USES THEREOF |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN112912400B (zh) | 2018-10-19 | 2025-05-30 | 明尼苏达大学董事会 | Nk接合子分子及其使用方法 |
| US20210386788A1 (en) | 2018-10-24 | 2021-12-16 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| JP2022505921A (ja) * | 2018-10-26 | 2022-01-14 | カファ セラピューティクス リミテッド | Ｃｌｌ１を標的とする抗体およびその応用 |
| EP3873540A4 (en) | 2018-10-31 | 2022-07-27 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR THE TREATMENT OF CANCER |
| WO2020092839A1 (en) | 2018-10-31 | 2020-05-07 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| KR102335799B1 (ko) * | 2018-12-05 | 2021-12-08 | 주식회사 헤지호그 | 엔도텔린 수용체 a 활성 조절 항체 |
| US12227566B2 (en) | 2018-12-05 | 2025-02-18 | Hedgehog, Inc. | Endothelin receptor type a activity regulating antibody |
| WO2020123716A1 (en) | 2018-12-11 | 2020-06-18 | Obsidian Therapeutics, Inc. | Membrane bound il12 compositions and methods for tunable regulation |
| KR20210104772A (ko) | 2018-12-14 | 2021-08-25 | 블루버드 바이오, 인코포레이티드. | 이량체화제로 조절된 면역수용체 복합체 |
| KR20210106437A (ko) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
| CA3123519A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| CN113490528B (zh) | 2019-02-15 | 2024-12-03 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| WO2020172553A1 (en) | 2019-02-22 | 2020-08-27 | Novartis Ag | Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors |
| US20220152150A1 (en) | 2019-02-25 | 2022-05-19 | Novartis Ag | Mesoporous silica particles compositions for viral delivery |
| MX2021010840A (es) | 2019-03-08 | 2022-01-19 | Obsidian Therapeutics Inc | Composiciones de anhidrasa carbónica 2 (ca2) humana y métodos de regulación ajustable. |
| MX2021010857A (es) | 2019-03-11 | 2021-12-15 | Janssen Biotech Inc | Anticuerpos biespecificos anti-v(beta17)/anti-cd123. |
| SG11202110613SA (en) * | 2019-03-27 | 2021-10-28 | Res Inst Nationwide Childrens Hospital | Generation of chimeric antigen receptor (car)-primary nk cells for cancer immunotherapy using a combination of cas9/rnp and aav viruses |
| EP3953455A1 (en) | 2019-04-12 | 2022-02-16 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
| EP3959320A1 (en) | 2019-04-24 | 2022-03-02 | Novartis AG | Compositions and methods for selective protein degradation |
| BR112021020999A2 (pt) | 2019-05-04 | 2021-12-14 | Inhibrx Inc | Polipeptídeos de ligação à clec12a e usos dos mesmos |
| KR20220031549A (ko) * | 2019-05-08 | 2022-03-11 | 2세븐티 바이오, 인코포레이티드 | Cll-1 표적화 면역요법 |
| JP2022537670A (ja) | 2019-06-12 | 2022-08-29 | オブシディアン セラピューティクス， インコーポレイテッド | Ｃａ２の組成物および調整可能な制御方法 |
| EP3983537A1 (en) | 2019-06-12 | 2022-04-20 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| EP4010697A4 (en) * | 2019-08-05 | 2022-10-12 | Charles River Laboratories, Inc. | ANTIGEN-BINDING MOLECULES AND THEIR SCREENING METHODS |
| WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| AU2020346887A1 (en) * | 2019-09-13 | 2022-04-07 | Memorial Hospital For Cancer And Allied Diseases | Antigen recognizing receptors targeting CD371 and uses thereof |
| EP4065157A1 (en) | 2019-11-26 | 2022-10-05 | Novartis AG | Cd19 and cd22 chimeric antigen receptors and uses thereof |
| IL293215A (en) | 2019-11-26 | 2022-07-01 | Novartis Ag | Chimeric antigen receptors that bind bcma and cd19 and their uses |
| BR112022011902A2 (pt) | 2019-12-20 | 2022-09-06 | Novartis Ag | Terapias de combinação |
| CN115210252A (zh) | 2020-02-04 | 2022-10-18 | 西雅图儿童医院（Dba西雅图儿童研究所） | 抗二硝基苯酚的嵌合抗原受体 |
| EP4100054A4 (en) * | 2020-02-07 | 2024-07-17 | Washington University | PROTECTIVE ANTIBODIES AGAINST INFLUENZA B |
| CN115397460A (zh) | 2020-02-27 | 2022-11-25 | 诺华股份有限公司 | 制备表达嵌合抗原受体的细胞的方法 |
| EP4110376A2 (en) | 2020-02-27 | 2023-01-04 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
| GB202005216D0 (en) * | 2020-04-08 | 2020-05-20 | Autolus Ltd | Cell |
| JP2023529211A (ja) | 2020-06-11 | 2023-07-07 | ノバルティス アーゲー | Ｚｂｔｂ３２阻害剤及びその使用 |
| KR20230027056A (ko) | 2020-06-23 | 2023-02-27 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 |
| JP7819176B2 (ja) | 2020-08-03 | 2026-02-24 | ノバルティス アーゲー | ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| EP4192873A1 (en) * | 2020-08-10 | 2023-06-14 | Julius-Maximilians-Universität Würzburg | Siglec-6-binding polypeptides |
| MX2023002107A (es) | 2020-08-21 | 2023-03-15 | Novartis Ag | Composiciones y metodos para la generacion in vivo de celulas que expresan car. |
| TW202227495A (zh) | 2020-09-11 | 2022-07-16 | 美商健生生物科技公司 | 用於調節β鏈介導之免疫的方法及組成物 |
| WO2022056197A1 (en) | 2020-09-11 | 2022-03-17 | Janssen Biotech, Inc. | Immune targeting molecules and uses thereof |
| US20220089737A1 (en) * | 2020-09-11 | 2022-03-24 | Janssen Biotech, Inc. | Multi-specific immune targeting molecules and uses thereof |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| WO2022229853A1 (en) | 2021-04-27 | 2022-11-03 | Novartis Ag | Viral vector production system |
| CN113461818B (zh) * | 2021-06-30 | 2022-01-21 | 徐州医科大学 | 靶向CD276的全人源抗体scFv、嵌合抗原受体、工程化免疫细胞及其制备方法 |
| US20250082681A1 (en) * | 2021-07-30 | 2025-03-13 | Nanjing Legend Biotech Co., Ltd. | Antibodies against cll1 and constructs thereof |
| EP4388000A1 (en) | 2021-08-20 | 2024-06-26 | Novartis AG | Methods of making chimeric antigen receptor?expressing cells |
| US12279845B2 (en) | 2021-10-18 | 2025-04-22 | Cilag Gmbh International | Cable-driven actuation system for robotic surgical tool attachment |
| CA3248167A1 (en) * | 2022-04-11 | 2023-10-19 | Vor Biopharma Inc. | LIAISON AGENTS AND THEIR METHODS OF USE |
| CN119816591A (zh) * | 2022-04-29 | 2025-04-11 | 贝勒医学院 | 末端脱氧核苷酰转移酶抗体及其用途 |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| WO2023225641A2 (en) * | 2022-05-20 | 2023-11-23 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Compositions and methods for targeting clec12a-expressing cancers |
| US20240091261A1 (en) | 2022-08-26 | 2024-03-21 | Kite Pharma, Inc. | Immune cell function |
| GB202214132D0 (en) | 2022-09-27 | 2022-11-09 | Coding Bio Ltd | CLL1 binding molecules |
| AU2023369684A1 (en) | 2022-10-26 | 2025-04-17 | Novartis Ag | Lentiviral formulations |
| WO2024149225A1 (zh) * | 2023-01-10 | 2024-07-18 | 合源康华医药科技(北京)有限公司 | 一种人源化cll1抗体、嵌合抗原受体及其应用 |
| GB202301949D0 (en) | 2023-02-10 | 2023-03-29 | Coding Bio Ltd | CLL1 and/or CD33 binding molecules |
| PE20252789A1 (es) | 2023-05-24 | 2025-12-22 | Kumquat Biosciences Inc | Compuestos heterociclicos y usos de estos |
| TW202541841A (zh) * | 2023-12-20 | 2025-11-01 | 美商黛安瑟斯醫療運營公司 | 用於治療ｃ１ｓ介導病症的包含抗體的醫藥組成物及其使用方法 |
Family Cites Families (180)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5906936A (en) | 1988-05-04 | 1999-05-25 | Yeda Research And Development Co. Ltd. | Endowing lymphocytes with antibody specificity |
| US6303121B1 (en) | 1992-07-30 | 2001-10-16 | Advanced Research And Technology | Method of using human receptor protein 4-1BB |
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| WO1992010591A1 (en) | 1990-12-14 | 1992-06-25 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| US6004811A (en) | 1991-03-07 | 1999-12-21 | The Massachussetts General Hospital | Redirection of cellular immunity by protein tyrosine kinase chimeras |
| US7049136B2 (en) | 1991-03-07 | 2006-05-23 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
| IE920716A1 (en) | 1991-03-07 | 1992-09-09 | Gen Hospital Corp | Redirection of cellular immunity by receptor chimeras |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
| US7211259B1 (en) | 1993-05-07 | 2007-05-01 | Immunex Corporation | 4-1BB polypeptides and DNA encoding 4-1BB polypeptides |
| DE69528894T2 (de) | 1994-05-02 | 2003-03-27 | Bernd Groner | Bifunktionelles protein, herstellung und verwendung |
| US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| US6103521A (en) | 1995-02-06 | 2000-08-15 | Cell Genesys, Inc. | Multispecific chimeric receptors |
| ATE297986T1 (de) | 1995-02-24 | 2005-07-15 | Gen Hospital Corp | Neuorientierung der zellulären immunität durch rezeptorchimären |
| GB9526131D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Recombinant chimeric receptors |
| US5874240A (en) | 1996-03-15 | 1999-02-23 | Human Genome Sciences, Inc. | Human 4-1BB receptor splicing variant |
| US5792648A (en) | 1996-07-31 | 1998-08-11 | Incyte Pharmaceuticals, Inc. | Human macrophage antigen |
| US20030060444A1 (en) | 1997-06-25 | 2003-03-27 | Celltech Therapeutics, Ltd. | Cell activation process and reagents therefor |
| EP1109921A4 (en) | 1998-09-04 | 2002-08-28 | Sloan Kettering Inst Cancer | FUSION RECEPTORS SPECIFIC TO MEMBRANE SPECIFIC PROSTATIC ANTIGEN AND USES THEREOF |
| US6410319B1 (en) | 1998-10-20 | 2002-06-25 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| WO2000063374A1 (en) | 1999-04-16 | 2000-10-26 | Celltech Therapeutics Limited | Synthetic transmembrane components |
| GB9925848D0 (en) | 1999-11-01 | 1999-12-29 | Celltech Therapeutics Ltd | Biological products |
| ATE419354T1 (de) | 2000-02-25 | 2009-01-15 | Us Gov Health & Human Serv | Scfv-moleküle gegen egfrviii mit verbesserter zytotoxizität und ausbeute, darauf basierte immuntoxine, und verfahren zur deren verwendung |
| NZ521255A (en) | 2000-03-06 | 2007-01-26 | Univ Kentucky Res Found | Methods to impair hematologic cancer progenitor cells and compounds related thereto |
| AU2001259792B2 (en) | 2000-03-29 | 2005-12-22 | The Ohio State University Research Foundation | Methods of blocking tissue destruction by autoreactive T cells |
| IL136511A0 (en) | 2000-06-01 | 2001-06-14 | Gavish Galilee Bio Appl Ltd | Genetically engineered mhc molecules |
| GB0025307D0 (en) | 2000-10-16 | 2000-11-29 | Celltech Chiroscience Ltd | Biological products |
| ATE338124T1 (de) | 2000-11-07 | 2006-09-15 | Hope City | Cd19-spezifische umgezielte immunzellen |
| US7177912B1 (en) | 2000-12-22 | 2007-02-13 | Datacore Software Corporation | SCSI transport protocol via TCP/IP using existing network hardware and software |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| WO2002088334A1 (en) | 2001-04-30 | 2002-11-07 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US7514537B2 (en) | 2001-04-30 | 2009-04-07 | City Of Hope | Chimeric immunoreceptor useful in treating human gliomas |
| WO2003013598A2 (en) | 2001-08-09 | 2003-02-20 | Lam Dominic M K | Novel vaccine compositions and methods of vaccine preparation for veterinary and human diseases |
| US20030148982A1 (en) | 2001-11-13 | 2003-08-07 | Brenner Malcolm K. | Bi-spcific chimeric T cells |
| WO2003057171A2 (en) | 2002-01-03 | 2003-07-17 | The Trustees Of The University Of Pennsylvania | Activation and expansion of t-cells using an engineered multivalent signaling platform |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| US7638326B2 (en) | 2002-01-03 | 2009-12-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| US20040242504A1 (en) | 2003-05-30 | 2004-12-02 | Vadim Ivanov | Novel composition and method for the treatment of hypertension |
| JP2008501621A (ja) | 2003-05-31 | 2008-01-24 | マイクロメット アクツィエン ゲゼルシャフト | Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物 |
| EP2322547A1 (en) | 2003-06-25 | 2011-05-18 | Crucell Holland B.V. | Myeloid cell-specific lectin |
| KR20130065723A (ko) | 2003-06-27 | 2013-06-19 | 암젠 프레몬트 인코포레이티드 | 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도 |
| WO2005019429A2 (en) | 2003-08-22 | 2005-03-03 | Potentia Pharmaceuticals, Inc. | Compositions and methods for enhancing phagocytosis or phagocyte activity |
| WO2005023761A2 (en) | 2003-09-11 | 2005-03-17 | Kemia, Inc. | Cytokine inhibitors |
| ATE491953T1 (de) | 2003-09-15 | 2011-01-15 | Oklahoma Med Res Found | Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis |
| US20050113564A1 (en) | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| JP2007522447A (ja) | 2004-01-23 | 2007-08-09 | サノフィ パストゥール インコーポレイテッド | 細胞傷害性アッセイ |
| WO2005118788A2 (en) | 2004-05-27 | 2005-12-15 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| US7994298B2 (en) | 2004-09-24 | 2011-08-09 | Trustees Of Dartmouth College | Chimeric NK receptor and methods for treating cancer |
| WO2006060878A1 (en) | 2004-12-10 | 2006-06-15 | Peter Maccallum Cancer Institute | Methods and compositions for adoptive immunotherapy |
| US20060171929A1 (en) | 2005-01-31 | 2006-08-03 | The University Of Washington | Regulation of dendritic cell functions by the DCAL-2 receptor |
| JP2008541758A (ja) | 2005-06-02 | 2008-11-27 | アストラゼネカ エービー | Ｃｄ２０に対する抗体およびその使用 |
| US20070036773A1 (en) | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
| EP1795588A1 (en) | 2005-12-07 | 2007-06-13 | Cellerix, S.L. | Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease |
| WO2008045437A2 (en) | 2006-10-09 | 2008-04-17 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
| US20080131415A1 (en) | 2006-11-30 | 2008-06-05 | Riddell Stanley R | Adoptive transfer of cd8 + t cell clones derived from central memory cells |
| WO2008110491A2 (en) | 2007-03-09 | 2008-09-18 | University Of Basel | Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat |
| JP2008228690A (ja) | 2007-03-23 | 2008-10-02 | Mitsukan Group Honsha:Kk | 甘味を有するタンパク質 |
| SI2856876T1 (en) | 2007-03-30 | 2018-04-30 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| US8163279B2 (en) | 2007-04-13 | 2012-04-24 | Stemline Therapeutics, Inc. | IL3Rα antibody conjugates and uses thereof |
| EP2014680A1 (en) | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
| US20090088373A1 (en) | 2007-09-28 | 2009-04-02 | Gallo Richard L | Use of compositions to enhance innate immune response |
| US8536310B2 (en) | 2007-10-17 | 2013-09-17 | Arca Biopharma, Inc. | Antibodies to CLL-1 |
| WO2009097140A1 (en) | 2008-01-30 | 2009-08-06 | Memorial Sloan-Kettering Cancer Center | Methods for off -the -shelf tumor immunotherapy using allogeneic t-cell precursors |
| US8379824B2 (en) | 2008-03-06 | 2013-02-19 | At&T Intellectual Property I, Lp | Methods and apparatus to provide a network-based caller identification service in a voice over internet protocol network |
| WO2010012829A1 (en) | 2008-07-31 | 2010-02-04 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Her2/neu specific t cell receptors |
| CA2733203A1 (en) | 2008-08-05 | 2010-02-11 | Emory University | Use of mtor inhibitors to enhance t cell immune responses |
| EP2331566B1 (en) | 2008-08-26 | 2015-10-07 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| ES2645692T3 (es) | 2008-11-11 | 2017-12-07 | The Board Of Regents,The University Of Texas System | Microcápsulas de rapamicina y su uso para el tratamiento del cáncer |
| EP2375897A4 (en) | 2009-01-14 | 2013-05-15 | Health Research Inc | METHOD AND COMPOSITIONS USING MTOR-INHIBITORS FOR IMPROVING IMMUNE REACTIONS |
| WO2010085660A2 (en) | 2009-01-23 | 2010-07-29 | Roger Williams Hospital | Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same |
| JP2013525260A (ja) * | 2009-04-17 | 2013-06-20 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 急性骨髄性白血病を治療するための組成物および方法 |
| EP2470212A4 (en) | 2009-10-01 | 2013-12-04 | Csl Ltd | METHOD FOR TREATING POSITIVE PHILADELPHIA CHROMOSOME LEUKEMIA |
| CA2776143A1 (en) | 2009-10-01 | 2011-04-07 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| ES2724451T3 (es) | 2010-02-04 | 2019-09-11 | Univ Pennsylvania | ICOS regula fundamentalmente la expansión y la función de linfocitos Th17 humanos inflamatorios |
| SE535129C2 (sv) | 2010-07-13 | 2012-04-24 | Bostik Ab | Komposition för vidhäftning av ett golvmaterial |
| CN103068846B9 (zh) | 2010-08-24 | 2016-09-28 | 弗·哈夫曼-拉罗切有限公司 | 包含二硫键稳定性Fv片段的双特异性抗体 |
| WO2012033885A1 (en) | 2010-09-08 | 2012-03-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered gd2-specific t cells |
| MX2013004792A (es) | 2010-10-27 | 2013-08-27 | Baylor College Medicine | Receptor cd27 quimericos para redirigir celulas t a malignidades cd70-positivas. |
| EP3974453A3 (en) | 2010-11-16 | 2022-08-03 | Amgen Inc. | Agents and methods for treating diseases that correlate with bcma expression |
| US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
| KR101400194B1 (ko) | 2010-12-01 | 2014-05-27 | 제일모직 주식회사 | 컬러필터용 감광성 수지 조성물 및 이를 이용한 컬러필터 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US9233125B2 (en) | 2010-12-14 | 2016-01-12 | University Of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer |
| KR20140004174A (ko) | 2011-01-18 | 2014-01-10 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암 치료를 위한 조성물 및 방법 |
| US9987308B2 (en) | 2011-03-23 | 2018-06-05 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| WO2012127464A2 (en) | 2011-03-23 | 2012-09-27 | Gavish-Galilee Bio Applications Ltd | Constitutively activated t cells for use in adoptive cell therapy |
| MX2013011363A (es) | 2011-04-01 | 2014-04-25 | Sloan Kettering Inst Cancer | Anticuerpos para peptidos citosolicos. |
| CA2832569A1 (en) | 2011-04-08 | 2012-10-11 | Baylor College Of Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
| CA2832540C (en) | 2011-04-08 | 2020-09-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer |
| US20130071414A1 (en) | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| KR101972446B1 (ko) | 2011-05-27 | 2019-04-25 | 글락소 그룹 리미티드 | Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）결합 단백질 |
| CN103764668B (zh) | 2011-07-09 | 2016-08-17 | 加利福尼亚大学董事会 | 白血病干细胞靶向配体及应用方法 |
| EP2736539B1 (en) | 2011-07-25 | 2017-08-23 | Nationwide Children's Hospital, Inc. | Recombinant virus products and methods for inhibition of expression of dux4 |
| MX2014001222A (es) | 2011-07-29 | 2014-09-15 | Univ Pennsylvania | Receptores coestimuladores de cambio. |
| WO2013026837A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| WO2013026839A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
| NO2748201T3 (enExample) | 2011-08-23 | 2018-05-12 | ||
| WO2013033626A2 (en) | 2011-08-31 | 2013-03-07 | Trustees Of Dartmouth College | Nkp30 receptor targeted therapeutics |
| CN103946952A (zh) | 2011-09-16 | 2014-07-23 | 宾夕法尼亚大学董事会 | 用于治疗癌症的rna改造的t细胞 |
| EP3326467B1 (en) | 2011-09-16 | 2020-03-11 | Baylor College of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| ES2654060T3 (es) | 2011-10-20 | 2018-02-12 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Receptores de antígenos quiméricos anti-CD22 |
| US9688740B2 (en) | 2011-10-26 | 2017-06-27 | National Cancer Center | Mutant CTLA4 gene transfected T cell and composition including same for anticancer immunotherapy |
| US9272002B2 (en) | 2011-10-28 | 2016-03-01 | The Trustees Of The University Of Pennsylvania | Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
| US10391126B2 (en) | 2011-11-18 | 2019-08-27 | Board Of Regents, The University Of Texas System | CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA |
| HUE033245T2 (hu) | 2011-12-19 | 2017-11-28 | Synimmune Gmbh | Bispecifikus ellenanyag molekula |
| CA2861491C (en) | 2012-02-13 | 2020-08-25 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| EP2817330B1 (en) | 2012-02-22 | 2020-07-08 | The Trustees of the University of Pennsylvania | Use of icos-based cars to enhance antitumor activity and car persistence |
| CA3285826A1 (en) | 2012-02-22 | 2026-03-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| WO2013126729A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Use of the cd2 signaling domain in second-generation chimeric antigen receptors |
| KR20140145148A (ko) * | 2012-03-21 | 2014-12-22 | 에리테끄 파르마 | 급성 골수성 백혈병 치료를 위한 약제 |
| EP2828290B1 (en) | 2012-03-23 | 2018-08-15 | The United States of America, represented by the Secretary, Department of Health and Human Services | Anti-mesothelin chimeric antigen receptors |
| RU2766608C2 (ru) | 2012-04-11 | 2022-03-15 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток |
| US20130271355A1 (en) | 2012-04-13 | 2013-10-17 | Nokia Corporation | Multi-segment wearable accessory |
| US9163090B2 (en) | 2012-05-07 | 2015-10-20 | Cellerant Therapeutics, Inc. | Antibodies specific for CLL-1 |
| PT2850106T (pt) | 2012-05-18 | 2022-07-18 | Aptevo Res & Development Llc | Imunofusão biespecífica (bif) de scfv de ligação a cd123 e cd3 |
| CN103483452B (zh) | 2012-06-12 | 2021-08-13 | 上海细胞治疗集团有限公司 | 双信号独立的嵌合抗原受体及其用途 |
| US20150290244A1 (en) | 2012-07-13 | 2015-10-15 | The Trustees Of The University Of Pennsylvania | Use of cart19 to deplete normal b cells to induce tolerance |
| HRP20230297T1 (hr) | 2012-07-13 | 2023-05-12 | The Trustees Of The University Of Pennsylvania | UPRAVLJANJE TOKSIČNOŠĆU ZA ANTI-TUMORSKO DJELOVANJE CAR-a |
| JP6482461B2 (ja) | 2012-07-13 | 2019-03-13 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 投与に関する形質導入ｔ細胞の適合性の評価方法 |
| EP2872617A4 (en) | 2012-07-13 | 2015-12-09 | Univ Pennsylvania | EPITOP SPREADING IN CONNECTION WITH CAR T CELLS |
| US20150140019A1 (en) | 2012-07-13 | 2015-05-21 | The Trustees Of The University Of Pennsylvania | Compositions and Methods for Regulating CAR T Cells |
| JP2015524255A (ja) | 2012-07-13 | 2015-08-24 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 二重特異性抗体を共導入することによってｃａｒｔ細胞の活性を強化する方法 |
| BR122020002986A8 (pt) | 2012-08-20 | 2023-04-18 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Método e composições para imunoterapia celular |
| WO2014039513A2 (en) | 2012-09-04 | 2014-03-13 | The Trustees Of The University Of Pennsylvania | Inhibition of diacylglycerol kinase to augment adoptive t cell transfer |
| HUE042040T2 (hu) | 2012-09-27 | 2019-06-28 | Merus Nv | Bispecifikus IGG antitestek mint T-sejt kapcsolók |
| CN102875685B (zh) | 2012-09-29 | 2013-12-25 | 郑骏年 | 嵌合抗原受体hFⅦL-CD8-OX40-CD3ζ及其用途 |
| WO2014055442A2 (en) | 2012-10-01 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting stromal cells for the treatment of cancer |
| WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| WO2014068079A1 (en) | 2012-11-01 | 2014-05-08 | Max-Delbrück-Centrum für Molekulare Medizin | An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| CN113005091A (zh) | 2013-02-06 | 2021-06-22 | 细胞基因公司 | 具有改进特异性的修饰的t淋巴细胞 |
| US9573988B2 (en) | 2013-02-20 | 2017-02-21 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
| JP6647868B2 (ja) | 2013-02-20 | 2020-02-14 | ノバルティス アーゲー | ヒト化抗ＥＧＦＲｖＩＩＩキメラ抗原受容体を用いたがんの処置 |
| CN103113470B (zh) | 2013-02-27 | 2015-04-22 | 四川大学 | 靶向人egfr的基因工程化淋巴细胞及其制备方法和用途 |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| WO2014145252A2 (en) | 2013-03-15 | 2014-09-18 | Milone Michael C | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| US10584158B2 (en) | 2013-04-17 | 2020-03-10 | Baylor College Of Medicine | Immunosuppressive TGF-β signal converter |
| EP3783098A1 (en) | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| ES2918501T3 (es) | 2013-12-19 | 2022-07-18 | Novartis Ag | Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| WO2015112626A1 (en) | 2014-01-21 | 2015-07-30 | June Carl H | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| US20170335281A1 (en) | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| ES2857226T3 (es) | 2014-03-15 | 2021-09-28 | Novartis Ag | Receptor de antígeno quimérico regulable |
| TWI719942B (zh) | 2014-07-21 | 2021-03-01 | 瑞士商諾華公司 | 使用ｃｄ３３嵌合抗原受體治療癌症 |
| US20170226495A1 (en) | 2014-07-21 | 2017-08-10 | Novartis Ag | Sortase molecules and uses thereof |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| JP2017528433A (ja) | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ |
| US20170274014A1 (en) | 2014-07-21 | 2017-09-28 | Jennifer Brogdon | Combinations of low, immune enhancing, doses of mtor inhibitors and cars |
| BR112017001183A2 (pt) | 2014-07-21 | 2017-11-28 | Novartis Ag | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado |
| SG10201913782UA (en) | 2014-07-21 | 2020-03-30 | Novartis Ag | Treatment of cancer using a cll-1 chimeric antigen receptor |
| EP4205749A1 (en) | 2014-07-31 | 2023-07-05 | Novartis AG | Subset-optimized chimeric antigen receptor-containing cells |
| AU2015301460B2 (en) | 2014-08-14 | 2021-04-08 | Novartis Ag | Treatment of cancer using GFR alpha-4 chimeric antigen receptor |
| MX2017002205A (es) | 2014-08-19 | 2017-08-21 | Novartis Ag | Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer. |
| JP6839074B2 (ja) | 2014-09-17 | 2021-03-03 | ノバルティス アーゲー | 養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング |
| KR20170068504A (ko) | 2014-10-08 | 2017-06-19 | 노파르티스 아게 | 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도 |
| WO2016061368A1 (en) | 2014-10-15 | 2016-04-21 | The Children's Hospital Of Philadelphia | Compositions and methods for treating b-lymphoid malignancies |
| RU2021118125A (ru) | 2014-12-29 | 2022-04-06 | Новартис Аг | Способы получения экспрессирующих химерный антигенный рецептор клеток |
| US11459390B2 (en) | 2015-01-16 | 2022-10-04 | Novartis Ag | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| ES2876974T3 (es) | 2015-04-07 | 2021-11-15 | Novartis Ag | Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina |
| JP6961490B2 (ja) | 2015-04-08 | 2021-11-05 | ノバルティス アーゲー | Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法 |
| AU2016249005B2 (en) | 2015-04-17 | 2022-06-16 | Novartis Ag | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| EP3286211A1 (en) | 2015-04-23 | 2018-02-28 | Novartis AG | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| CA2992551A1 (en) | 2015-07-21 | 2017-01-26 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
| WO2017040930A2 (en) | 2015-09-03 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Biomarkers predictive of cytokine release syndrome |
| AU2016323985B2 (en) | 2015-09-17 | 2022-12-15 | Novartis Ag | CAR T cell therapies with enhanced efficacy |
| EP4643874A3 (en) | 2015-12-22 | 2026-02-11 | Novartis AG | Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy |
| RU2018127657A (ru) | 2015-12-30 | 2020-01-31 | Новартис Аг | Виды терапии на основе иммуноэффекторных клеток с улучшенной эффективностью |
| AU2017302668B9 (en) | 2016-07-28 | 2023-06-22 | Novartis Ag | Combination therapies of chimeric antigen receptors and PD-1 inhibitors |
| BR112019002035A2 (pt) | 2016-08-01 | 2019-05-14 | Novartis Ag | tratamento de câncer usando um receptor de antígeno quimérico em combinação com um inibidor de uma molécula pró-macrófago m2 |
| BR112019006781A2 (pt) | 2016-10-07 | 2019-07-30 | Novartis Ag | receptores de antígeno quiméricos para o tratamento de câncer |
-
2015
- 2015-07-21 SG SG10201913782UA patent/SG10201913782UA/en unknown
- 2015-07-21 TW TW104123638A patent/TWI718992B/zh not_active IP Right Cessation
- 2015-07-21 US US14/805,075 patent/US10568947B2/en active Active
- 2015-07-21 BR BR112017000939A patent/BR112017000939A2/pt not_active IP Right Cessation
- 2015-07-21 CN CN201580050589.9A patent/CN107109420A/zh active Pending
- 2015-07-21 CA CA2955465A patent/CA2955465A1/en not_active Abandoned
- 2015-07-21 JP JP2017503488A patent/JP6736540B2/ja not_active Expired - Fee Related
- 2015-07-21 MX MX2017001013A patent/MX2017001013A/es unknown
- 2015-07-21 AU AU2015292811A patent/AU2015292811B2/en not_active Ceased
- 2015-07-21 SG SG11201700418VA patent/SG11201700418VA/en unknown
- 2015-07-21 EP EP15744448.0A patent/EP3171882A1/en not_active Withdrawn
- 2015-07-21 RU RU2017105161A patent/RU2741120C2/ru active
- 2015-07-21 WO PCT/US2015/041337 patent/WO2016014535A1/en not_active Ceased
- 2015-07-21 KR KR1020177004392A patent/KR20170037625A/ko not_active Ceased
- 2015-07-21 AR ARP150102310A patent/AR101829A1/es unknown
-
2017
- 2017-01-15 IL IL250116A patent/IL250116B/en active IP Right Grant
- 2017-01-20 CO CONC2017/0000506A patent/CO2017000506A2/es unknown
-
2019
- 2019-12-27 US US16/728,557 patent/US20200215171A1/en not_active Abandoned
-
2020
- 2020-03-18 AU AU2020201939A patent/AU2020201939A1/en not_active Abandoned
- 2020-07-15 JP JP2020121501A patent/JP2020185001A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017522879A5 (enExample) | ||
| JP2017522880A5 (enExample) | ||
| JP2025032091A5 (enExample) | ||
| CN108276493B (zh) | 一种嵌合抗原受体及其应用 | |
| JP2017530694A5 (enExample) | ||
| RU2017105160A (ru) | Лечение рака с помощью химерного антигенного рецептора к cd33 | |
| JP2017527271A5 (enExample) | ||
| JP2017524367A5 (enExample) | ||
| US12161668B2 (en) | T cells expressing a chimeric antigen receptor | |
| RU2020117196A (ru) | Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей | |
| RU2017105161A (ru) | Лечение рака с использованием химерного антигенного рецептора cll-1 | |
| RU2017105065A (ru) | Лечение злокачественного новообразования с использованием гуманизированного химерного антигенного рецептора против всма | |
| EP3875484A1 (en) | Cll1-targeting antibody and application thereof | |
| JP2018538339A5 (enExample) | ||
| JP2019523301A5 (enExample) | ||
| EP3609914A1 (en) | Chimeric antigen receptor t cells targeting the tumor microenvironment | |
| US12600760B2 (en) | Chimeric antigen receptors targeting CD79B and CD19 | |
| WO2018132506A1 (en) | Chimeric antigen receptors based on alternative signal 1 domains | |
| CN116829194A (zh) | 用于工程化细胞疗法的靶向细胞因子构建体 | |
| AU2025279733A1 (en) | Rituximab-resistant chimeric antigen receptors and uses thereof | |
| WO2018226958A1 (en) | T cells expressing a chimeric antigen receptor | |
| AU2025202029A1 (en) | Chimeric antigen receptors targeting CD37 | |
| CA3053592A1 (en) | Antibody targeting il-13ra2 and use thereof | |
| JP2022539587A (ja) | Ｂ細胞悪性腫瘍の処置のために細胞表面マーカーｃｄ７２を標的とする免疫療法 | |
| US20240150456A1 (en) | Engineered immune cells and uses thereof |